AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials
As the oral weight-loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its candidate …
Post
-
-
Zenas’ MS drug reduces new brain lesion formation by 95% in Phase II trial
Autoimmune specialist Zenas BioPharma has posted a win for its lead candidate, obexelimab, from a mid-stage study in relapsing multiple …
-
Breye Therapeutics’ oral retinopathy drug shows early improvement in disease activity
Breye Therapeutics’ oral small molecule for non-proliferative diabetic retinopathy (NPDR) has demonstrated safety and early signs of improving disease activity …
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained …
-
Brazilian study shows increase in Covid-19-era substance abuse-related deaths
The societal and economic impacts of the Covid-19 pandemic included a variety of downstream effects on health endpoints worldwide. Among …
-
A New Strategic Blueprint: Designing Smarter Early Phase Trials in Oncology
Cancer drugs form one of the most dynamic segments of pharmaceuticals, powered by rising incidence, ageing populations, deeper cancer biology, …
-
VectorY doses first participant in Phase I/II PIONEER-ALS trial
VectorY Therapeutics has dosed the first participant in its Phase I/II PIONEER-ALS clinical trial, which is investigating VTx-002, a vectorised …
-
By the Numbers: Oncology Trial Activation Timelines and Global Reach
The volume of current activity in the oncology space is enormous. GlobalData’s clinical trial database – a repository of data …
-
Veradermics concludes enrolment in second Phase III VDPHL01 trial
Veradermics has completed enrolment in its second pivotal Phase III clinical trial of VDPHL01 for male pattern hair loss treatment. The …
-
Priovant advances CS drug to Phase III after 100% response in Phase II
Priovant Therapeutics’ cutaneous sarcoidosis (CS) drug has shown response rates of up to 100% on endpoints in a Phase II …
-
Magazine: Smart and connected packaging
With the recent conclusion of PharmaPack 2026, this month’s magazine is focused on the key messaging that emanated from the event. With the …
-
Lumosa’s stroke drug shows potential on double Phase II win
Lumosa Therapeutics has posted positive results from two independent Phase II clinical trials of its lead asset, odatroltide (LT3001) in …
-
SLE: four trials to watch in 2026
As Spring edges closer, rheumatology experts are preparing for The European Lupus Society’s 15th Annual European Lupus Meeting, which will …
-
FDA approves PharmaResearch IND application for PRD-101 trial
The US Food and Drug Administration (FDA) has granted clearance for PharmaResearch’s PRD-101 investigational new drug (IND) application, enabling the …
-
Genentech reports fenebrutinib Phase III results for PPMS
Roche’s Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, …
